Novel Treatment Options for Metastatic NSCLC: A Focus on EGFR and MET Alterations and Strategies to Combat Adverse Events
Lyudmila Bazhenova, MD
Professor of Medicine
University of California, San Diego
Jamie E. Chaft, MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
Jonathan Goldman, MD
University of California, Los Angeles
Corey J. Langer, MD, FACP
Director of Thoracic Oncology
Abramson Cancer Center, Hospital of the University of Pennsylvania
Joel W. Neal, MD, PhD
Associate Professor of Medicine (Oncology)
Stanford University Medical Center
Provided by HMP Education, an HMP Global Company.
For questions regarding this educational activity, or to cancel your account, please call 609-371-1137 or email email@example.com.
This activity is designed to meet the educational needs of medical oncologists, nurses, nurse practitioners, physician assistants, pathologists, pulmonologists, oncology pharmacists, researchers, internists wishing to have an update on the diagnosis and management of lung cancer, and other healthcare professionals interested in the care and treatment of patients with thoracic malignancies.
After participating in this activity, learners should be better able to:
- Describe testing and 1st – 3rd line treatment options for metastatic NSCLC according to current guidelines with a focus on EGFR and MET alterations
- Evaluate current clinical data concerning the efficacy, safety, and potential sequencing of EGFR and MET-targeted therapies
- Implement strategies to anticipate and address/mitigate the most common and serious adverse events associated with EGFR and MET-targeted therapies in NSCLC
This on-demand webcast is available with synchronized slides and video/audio.
To be eligible for credit, participants must complete the educational activity, complete the 4-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: January 20, 2023
Expiration Date: January 20, 2024
Estimated Time to Complete: 1.75 hour
There is no fee associated with this activity.
The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications.
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.
HMP Education designates this internet live/enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This internet live/enduring, knowledge-based activity (Universal Activity Number: XXXXXXXXXXXXX) has been approved for a maximum of 1.75 contact hours (.175 CEUs).
The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.
This continuing nursing education internet live/enduring activity awards 1.75 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.75 contact hours.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.75 AAPA Category 1 credits. Approval is valid until January 20, 2024. PAs should only claim credit commensurate with the extent of their participation.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own provider.
The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
All relevant financial relationships have been mitigated.
The faculty has reported the following:
Lyudmila Bazhenova: Advisory Board - Boehringer Ingelheim, Bristol Meyer Squibb, Daiichi Sankyo, Janssen Biotech, Merck Serono, Novartis Pharmaceuticals, Turning Point Therapeutics; Consultant - Neuvogen
Jamie E. Chaft: Consultant - AstraZeneca, BMS
Jonathan Goldman: Advisory Board - AstraZeneca, Genentech, Jazz Pharmaceuticals; Consultant - AstraZeneca, Genentech; Grant/Research Support - AstraZeneca, Genentech, GSK, Merck, Pfizer
Corey J. Langer: Consultant - AstraZeneca; Grant/Research Support - Pfizer, Lilly, Advantagene, Inovio, Celgene, Vertex, Ariad (Takeda), Merck, Stemcentrex, Genentech/Roche, AstraZeneca, Trizell, GSK, Guardant; Other Material Support(Data Safety Monitoring) - Lilly, Amgen, Peregrine, Incyte, SWOG, Oncocyte; Advisory Board - Bristol Myers Squibb, Lilly, Pfizer, Synta, Boehringer-Ingelheim, AstraZeneca, Novartis, Abbott, Genentech/Roche, Savient, Bayer/Onyx, Celgene, Clarient, Clovis, Guardant, Merck, Gilead
Joel W. Neal: Grant/Research Support - AbbVie, AdaptImmune, Boehringer Inhelheim, Exelixis, GSK, Janssen, Merck, Nektar Therapeutics, Novartis, Roche/Genentech, Takeda Pharmaceuticals U.S.A.; Advisory Board - Amgen, AstraZeneca, Blueprint Pharmaceuticals, Calithera Biosciences, D2G Oncology, Exelixis, Iovance Biotherapeutics, Jounce Therapeutics, Mirati Therapeutics, Natera, Regeneron Pharmaceuticals, Roche/Genentech, Sanofi/Regeneron, Surface Oncology, Takeda Pharmaceuticals, Turning Point Therapeutics; Consultant - Amgen, AstraZeneca, Blueprint Pharmaceuticals, Calithera Biosciences, D2G Oncology, Eli Lilly & Company, Iovance Biotherapeutics, Jounce Therapeutics, Mirati Therapeutics, Natera, Regeneron Pharmaceuticals, Roche/Genentech, Sanofi/Regeneron, Surface Oncology, Takeda Pharmaceuticals, Turning Point Therapeutics; Other Material Support/Honoraria - Biomedical Learning Institute CME, Clinical Care Options CME, CME Matters, Medical Educator Consortium, Medscape CME, MJH Life Sciences CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Research to Practice CME, Rockpointe CME
HMP Education planners and staff include Kelly Jackson; Samantha Joy; Kayli McGovern; Randy Robbin; and Andrea Zimmerman, EdD.
No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity needs accommodations, please call 609-371-1137.
HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2023 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Joy, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at firstname.lastname@example.org or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Joy will review the grievance and respond within 30 days of receiving the complaint.
Supported by an independent educational grant from Janssen Biotech, Inc.